Ten expression platforms under one roof
Prokaryotic, yeast, insect, mammalian and cell-free systems all sit in-house. The molecule decides the host — never the other way round.
BOT Bioscience
More than 10,000 recombinant proteins ready to ship from ten expression platforms — alongside monoclonal and polyclonal antibodies, CD antigens and matched pairs, with custom production routes for diagnostic development.
Featured Products
Everything we list is made and quality-checked on our own benches. That means the data sheet in your box reflects the exact vial you opened today — not a summary of a batch shipped years ago.
Growth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
View detailsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
View detailsRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
View detailsRabbit and goat sera raised against multi-epitope targets for broad recognition, with custom immunisation campaigns available from your antigen.
View detailsA CD antigen and anti-CD panel built for immunophenotyping, cell sorting and CAR-T research workflows.
View detailsCapture–detection pairs pre-screened in sandwich ELISA, CLIA and lateral-flow formats, selected for low background and strong signal.
View detailsHapten design, carrier conjugation and antibody generation for therapeutic drug monitoring, food-safety testing and environmental residue analysis.
View detailsCustom services
Custom projects clear the same QC release bar as catalogue items. The route to the product changes — the paperwork standard never does.
From antigen design through affinity-purified antiserum in 8–12 weeks, with ELISA titre curves documented at every bleed.
Peptides from 5–50 mg delivered at ≥95% HPLC purity, with KLH, BSA or OVA conjugation available for immunisation use.
Construct design to ≥90% pure protein — covering soluble expression screens, inclusion-body refolding and tag removal.
From immunisation to a stable, isotyped, sequence-defined hybridoma.
Broad epitope coverage, from a defined number of animals and bleeds.
Reagents that recognise the paratope, not the antigen.
Small molecules made immunogenic, without losing the epitope that matters.
Antibodies against targets that cannot be purified in a native state.
Specific for the modified residue, blind to the unmodified protein.
The animal expresses the antigen; you skip the protein.
Antigen expressed in vivo, from an mRNA delivered to the draining node.
Single-domain binders from camelid heavy-chain antibodies.
From crude supernatant or ascites to a formulation-ready batch.
From a frozen vial to grams, without changing the antibody.
Milligrams from a mouse, when in vitro culture will not deliver.
Sequence in, protein out — any format, any scale.
A clonal, sequence-defined supply that does not depend on a cell line's memory.
A production line that holds its titre after sixty passages.
Fab, F(ab')2, Fc and half-antibody, cut where you need the cut.
Enzyme, fluorophore, biotin or gold — attached where it does not block binding.
A fluorescent antibody that lights up only when it binds.
Rescue a drifting clone, or rebuild one that stopped performing.
Affinity, avidity and stoichiometry, measured rather than assumed.
Where the antibody binds, at peptide or at residue resolution.
Native heavy–light chain pairing, recovered one cell at a time.
Epitope-focused antibodies from chemically defined peptide antigens.
Monoclonal antibodies in six weeks, from mice that never see a long protocol.
Gene to purified protein, in the host that suits the target.
Chemically defined culture, without the fetal bovine serum variable.
Protein synthesis in a tube, without living cells in the way.
Hundreds of constructs expressed, screened and ranked in parallel.
Protein whose concentration you can defend, because it was assigned and verified.
A production cell that holds its output across every batch.
Making a formalin-fixed epitope visible again.
From a sequence to an immunogen, with the epitope left intact.
A seven-transmembrane receptor, extracted and still recognising its ligand.
Channels that open, close and conduct — extracted without losing the gate.
SLC transporters kept in a bilayer, where transport is possible.
The general workflow for targets that cannot leave the membrane.
A full project, from a sequence to a protein with a function you can measure.
Finding the environment that keeps a membrane protein folded — and keeping it.
Proof that a membrane protein preparation is what it claims to be.
A patch of bilayer, held in solution, sized to the protein.
Baculovirus-driven assembly, at the scale that structural work needs.
Particles assembled with the glycosylation and processing of a human cell.
Bacterial capsids — fast, cheap and engineered at the sequence level.
Self-assembling particles at fermentation scale, without baculovirus infrastructure.
Particles grown in Nicotiana benthamiana, in weeks and at agricultural scale.
Structure prediction and machine learning, applied where they actually help.
Designing an active site around the chemistry you want.
Iterate. Select. Iterate again — the method that still delivers most improved enzymes.
Stability, solubility, affinity and humanisation — the everyday engineering requests.
The sequence before the sequence — where expression yield is decided.
An experienced second opinion, before the experiment is paid for.
One biotin, one site, quantified — the label you can build an assay on.
Longer circulation, less aggregation — without burying the active site.
Defined attachment points, by enzyme, click chemistry or encoded handle.
The general conjugation service: any label, any protein, characterised honestly.
An enzyme on a solid support, still active after its fiftieth cycle.
Capture reagents with measured ligand density and honest capacity.
Labelling through the glycans — specific to the Fc, away from the paratope.
Native protein from the source material, in the fraction you need.
Turning insoluble aggregates into folded protein — with a screen, not with hope.
Below the LAL threshold, without destroying the protein.
Getting a protein to 100 mg/mL and still monomeric.
Driving residual HCP down without losing yield.
We match the host to the molecule — its solubility profile, glycosylation needs and end use — rather than forcing every target through whichever system is free.
Why BOT
Prokaryotic, yeast, insect, mammalian and cell-free systems all sit in-house. The molecule decides the host — never the other way round.
Each shipment arrives with the full record for that specific lot — purity gels, HPLC traces, activity assays and, for antibodies, the application image run on the same lot.
Bespoke peptides, proteins and antibodies are released against the same QC criteria as catalogue products. Custom route, identical standard.
Buffer troubleshooting or a stubborn Western blot gets answered by the scientist who ran the production batch — not routed to a generic support queue.
Publications & citations
A sample of recent publications whose methods sections reference BOT reagents. Each title links to the publisher's record.
Next step
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.